Fox Rothschild LLP Partner Laura Holm and her team represented client PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) in its underwritten public offering of 2.5 million units to raise gross proceeds of approximately $11.25 million before deducting underwriting discounts, commissions and other offering expenses.

PetVivo is an emerging biomedical device company that focuses on licensing and commercialization of innovative medical devices and therapeutics for pets. In the IPO, each unit was sold at a price of $4.50. The warrants will have a per share exercise price of $5.625, are exercisable immediately, and expire five years from the date of issuance.   The common shares and warrants began trading on the Nasdaq Capital Market under the symbols “PETV” and “PETVW” respectively, on August 11, 2021.

Holm focuses her practice on corporate law, mergers and acquisitions and public and private offerings.  She assists public companies with their Exchange Act filings, corporate governance and compliance programs, including advice on Regulation FD, insider trading, shareholder engagement, disclosure controls and procedures and compensation policies. 

She was assisted by Patrick Pazderka, Bradley Rodos and Eric Bielefeldt.

For further details on the PetVivo IPO, see the company’s press release.

^{As this article contains statements regarding past performance, please note that results may vary depending on your particular facts and legal circumstances.}